MA27644A1 - Sechage - Google Patents

Sechage

Info

Publication number
MA27644A1
MA27644A1 MA28276A MA28276A MA27644A1 MA 27644 A1 MA27644 A1 MA 27644A1 MA 28276 A MA28276 A MA 28276A MA 28276 A MA28276 A MA 28276A MA 27644 A1 MA27644 A1 MA 27644A1
Authority
MA
Morocco
Prior art keywords
sample
high viscosity
solvent
drying
samples
Prior art date
Application number
MA28276A
Other languages
English (en)
Inventor
Yves Mayeresse
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27644(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA27644A1 publication Critical patent/MA27644A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention a trait à un procédé de séchage de prélèvements biologiques et autres prélèvements instables, permettant de les conserver sous forme de liquides à haute viscosité. Le procédé consiste à préparer un prélèvement à protéger par dissolution et/ou mise en suspension d'un agent actif dans une solution contenant un agent de stabilisation, à soumettre ce prélèvement aux effets d'une température et d'une pression telles que le solvant s'évapore et ce, sans congélation ni formation de bulles, afin d'obtenir une mousse et à extraire le solvant jusqu'à ce que le prélèvement sèche en formant un liquide à haute viscosité.
MA28276A 2002-11-01 2005-05-11 Sechage MA27644A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method

Publications (1)

Publication Number Publication Date
MA27644A1 true MA27644A1 (fr) 2005-12-01

Family

ID=32234471

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28276A MA27644A1 (fr) 2002-11-01 2005-05-11 Sechage
MA28275A MA27551A1 (fr) 2002-11-01 2005-05-11 Composition immunogene

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA28275A MA27551A1 (fr) 2002-11-01 2005-05-11 Composition immunogene

Country Status (28)

Country Link
US (3) US7927858B2 (fr)
EP (3) EP1556477B1 (fr)
JP (2) JP2006504801A (fr)
KR (2) KR101130948B1 (fr)
AR (2) AR041881A1 (fr)
AT (1) ATE352316T1 (fr)
AU (2) AU2003287980B2 (fr)
BR (1) BR0315767A (fr)
CA (2) CA2503946C (fr)
CY (2) CY1119504T1 (fr)
DE (1) DE60311526T2 (fr)
DK (2) DK1556477T3 (fr)
ES (3) ES2280809T3 (fr)
HK (1) HK1085380A1 (fr)
HU (1) HUE034801T2 (fr)
IL (2) IL168054A (fr)
IS (2) IS3028B (fr)
LT (2) LT1556477T (fr)
MA (2) MA27644A1 (fr)
MX (3) MXPA05004528A (fr)
MY (2) MY132859A (fr)
NO (3) NO342741B1 (fr)
NZ (2) NZ539706A (fr)
PL (2) PL213647B1 (fr)
PT (2) PT2395073T (fr)
SI (2) SI1556477T1 (fr)
TW (2) TW200501981A (fr)
WO (2) WO2004039399A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556477B1 (fr) * 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Sechage
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
KR101228356B1 (ko) * 2004-04-08 2013-02-05 바이오매트리카 인코포레이티드 생명과학용 시료 보관 및 시료 관리의 통합
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
ES2470340T3 (es) * 2005-12-28 2014-06-23 Advanced Bionutrition Corporation Vehículo de administración para bacterias probi�ticas que comprende una matriz seca de polisac�ridos, sac�ridos y polioles en forma vítrea
EA015964B1 (ru) * 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
CN103933564A (zh) 2007-05-02 2014-07-23 葛兰素史密丝克莱恩生物有限公司 疫苗
ES2393160T3 (es) * 2007-05-18 2012-12-19 Medimmune, Llc Conservación de materiales bioactivos con espuma liofilizada
EP2167686A1 (fr) * 2007-06-16 2010-03-31 Enigma Diagnostics Ltd. Compositions
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
CN105147611A (zh) 2007-07-26 2015-12-16 圣诺菲·帕斯图尔有限公司 抗原佐剂组合物及其方法
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
MX2011012586A (es) 2009-05-26 2012-03-26 Advanced Bionutrition Corp Composicion de polvo seco estable que comprende microorganismos biologicamente activos y/o materiales bioactivos y metodos de elaboracion.
WO2011032108A2 (fr) * 2009-09-13 2011-03-17 Vu Truong-Le Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant
RU2535869C2 (ru) 2010-01-28 2014-12-20 Эдванст Бионутришн Корпорейшн Сухая стекловидная композиция для стабилизации и защиты биологически активного материала и способ ее получения
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
FR2960781B1 (fr) 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2012018639A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
WO2012018638A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
DK2603100T3 (en) 2010-08-13 2018-08-06 Advanced Bionutrition Corp DRY STABILIZING COMPOSITION FOR STORAGE OF BIOLOGICAL MATERIALS
BR112013005049A2 (pt) 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
WO2012075376A2 (fr) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Formulations de virus lyophilisées
EP2646051A4 (fr) 2010-12-02 2014-05-28 Oncolytics Biotech Inc Formulations de virus liquides
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
SG193963A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
CA2832560A1 (fr) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations a viscosite reduite
US20120294894A1 (en) 2011-05-20 2012-11-22 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
EP2934572A4 (fr) 2012-12-20 2016-11-23 Biomatrica Inc Formulations et procédés pour stabiliser des réactifs pcr
WO2015050177A1 (fr) * 2013-10-03 2015-04-09 日東電工株式会社 Préparation de vaccin antigrippal séchée, et procédé pour produire une préparation de vaccin antigrippal séchée
CA2934434C (fr) * 2013-12-19 2022-05-24 Crucell Holland B.V. Formulations ameliorees pour des virosomes.
SG10201807826XA (en) 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
CN113826612B (zh) 2014-06-10 2022-11-22 生物马特里卡公司 在环境温度下稳定凝血细胞
WO2016012385A1 (fr) * 2014-07-21 2016-01-28 Sanofi Pasteur Composition de vaccin comprenant du pvi et des cyclodextrines
AU2016287453A1 (en) 2015-06-30 2017-09-28 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
CN108347982A (zh) 2015-07-29 2018-07-31 高级生物营养公司 用于特殊饮食用途的稳定的干燥益生菌组合物
KR20180041237A (ko) * 2015-09-04 2018-04-23 인벤트프라이즈 엘엘씨 Vlp 안정화된 백신 조성물
AU2016368265B2 (en) 2015-12-08 2021-10-28 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
CN112739207A (zh) * 2018-09-28 2021-04-30 株式会社大塚制药工场 包含阿卡伯糖或水苏糖的哺乳动物细胞保存用液

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3682047D1 (de) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
WO1990006951A1 (fr) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutants de pneumolysine et vaccins contre le pneumocoque obtenus a partir de tels mutants
ZA907737B (en) 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
WO1992001460A1 (fr) 1990-07-16 1992-02-06 The University Of North Carolina Proteines antigeniques a action limitee par l'incorporation de fer tirees de la bacterie n. meningitidis et associees a la famille de toxines des hemolysines
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
DE69133622D1 (de) 1990-08-23 2009-10-01 Univ North Carolina Transferrin bindende Proteine aus Neisseria-Gonorrhoeae und Neisseria-Meningitidis. Ihre Verwendung in einem Impfstoff
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0911036A3 (fr) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Structure immunogene à double vecteur
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DE69323264D1 (de) 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
AU3191495A (en) 1994-08-09 1996-03-07 Nisshin Oil Mills, Ltd., The Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EP1090642B8 (fr) 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vaccins comprenant un conjugué antigènique de polysaccharide-protéine porteuse et une protéine porteuse libre
SK168497A3 (en) 1995-06-07 1998-07-08 Biochem Vaccines Inc Streptococcal heat shock proteins members of the hsp70 family
IL122482A (en) 1995-06-07 1999-10-28 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry foamed glass matrices and compositions obtained thereby
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
WO1997029773A1 (fr) 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
CA2256333A1 (fr) * 1996-05-29 1997-12-04 Victor Bronshtein Accroissement de la duree de conservation par vitrification
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
PL187935B1 (pl) * 1996-07-02 2004-11-30 Connaught Lab Multiwalentna kompozycja immunogenna i jej zastosowanie
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
EP0942983B2 (fr) 1996-10-31 2014-09-10 Human Genome Sciences, Inc. Antigenes et vaccins actifs contre streptococcus pneumoniae
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999003884A2 (fr) 1997-07-21 1999-01-28 North American Vaccine, Inc. Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2303105A1 (fr) 1997-09-15 1999-03-25 Pasteur Merieux Msd Vaccins multivalents
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
KR100769103B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
NZ507717A (en) 1998-04-07 2004-02-27 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1944371B1 (fr) 1998-05-01 2015-03-04 Novartis AG Antigènes de neisseria meningitidis et compositions
US6306345B1 (en) * 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
EP1144998A3 (fr) 1998-10-09 2002-08-07 Chiron Corporation Sequences genomiques de neisseria et procedes d'utilisation
CA2347849C (fr) 1998-10-22 2013-06-25 The University Of Montana Proteines omp85 de neisseria gonorrhoeae et de neisseria meningitidis, compositions renfermant lesdites proteines et methodes d'utilisation correspondantes
EP1133572A4 (fr) 1998-11-12 2005-06-15 Univ California Sequence genomique de chlamydia pneumoniae
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
EP1163000B1 (fr) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccin contre des antigenes de bacteries
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
EP1165796A2 (fr) 1999-04-09 2002-01-02 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
WO2001041800A2 (fr) 1999-12-02 2001-06-14 Chiron Corporation Compositions et procedes de stabilisation de molecules biologiques lors dune operation de lyophilisation
WO2001052885A1 (fr) 2000-01-17 2001-07-26 Chiron Spa Vaccin a base de vesicule de membrane externe (omv) comprenant des proteines de membrane externe du serogroupe b de n. meningitis
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
HU227613B1 (en) * 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
EP2591771A1 (fr) * 2002-04-11 2013-05-15 MedImmune, LLC Conservation de matières bio-actives au moyen de mousse lyophilisée
EP1556477B1 (fr) * 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Sechage
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
US8449865B2 (en) 2013-05-28
TW200501981A (en) 2005-01-16
AR041881A1 (es) 2005-06-01
JP2006504801A (ja) 2006-02-09
WO2004039399A1 (fr) 2004-05-13
US8409587B2 (en) 2013-04-02
TW200501980A (en) 2005-01-16
DE60311526D1 (de) 2007-03-15
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
IS7805A (is) 2005-04-18
IS7806A (is) 2005-04-18
NZ539613A (en) 2008-09-26
US7927858B2 (en) 2011-04-19
EP2395073B1 (fr) 2017-09-06
IS3028B (is) 2021-05-15
AU2003287980A1 (en) 2004-05-25
DK2395073T3 (en) 2017-10-23
MX343419B (es) 2016-11-04
KR101058978B1 (ko) 2011-08-23
CY1119504T1 (el) 2018-03-07
PL215237B1 (pl) 2013-11-29
KR20050075766A (ko) 2005-07-21
SI2395073T1 (sl) 2017-12-29
MA27551A1 (fr) 2005-10-03
LT2395073T (lt) 2017-11-10
NZ539706A (en) 2008-03-28
EP2395073A3 (fr) 2012-01-25
MXPA05004528A (es) 2005-07-26
ES2649048T3 (es) 2018-01-09
CA2503871C (fr) 2012-12-11
MY132859A (en) 2007-10-31
MXPA05004675A (es) 2005-06-08
KR20050084626A (ko) 2005-08-26
DK1556477T3 (en) 2017-10-23
NO344759B1 (no) 2020-04-14
AU2003287980B2 (en) 2009-06-25
PT1556477T (pt) 2017-11-14
NO20051998L (no) 2005-06-24
KR101130948B1 (ko) 2012-03-30
EP1556477B1 (fr) 2017-08-09
BR0315767A (pt) 2005-09-06
EP1575612A1 (fr) 2005-09-21
US20110159038A1 (en) 2011-06-30
WO2004039417A2 (fr) 2004-05-13
IL168052A0 (en) 2011-08-01
CA2503946C (fr) 2016-08-16
PL376950A1 (pl) 2006-01-09
EP2395073A2 (fr) 2011-12-14
NO20051998D0 (no) 2005-04-25
TWI332843B (en) 2010-11-11
CY1119362T1 (el) 2018-03-07
JP4579156B2 (ja) 2010-11-10
US20060127415A1 (en) 2006-06-15
US20060127414A1 (en) 2006-06-15
IL168054A (en) 2011-06-30
LT1556477T (lt) 2017-10-25
MY145693A (en) 2012-03-30
DE60311526T2 (de) 2007-10-31
ATE352316T1 (de) 2007-02-15
WO2004039417A3 (fr) 2004-12-16
PT2395073T (pt) 2017-11-24
NO20052010L (no) 2005-06-24
AU2003278166B2 (en) 2009-01-29
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
JP2006512406A (ja) 2006-04-13
ES2280809T3 (es) 2007-09-16
PL377170A1 (pl) 2006-01-23
CA2503946A1 (fr) 2004-05-13
NO20052010D0 (no) 2005-04-25
EP1556477A2 (fr) 2005-07-27
AU2003278166A1 (en) 2004-05-25
AR041880A1 (es) 2005-06-01
PL213647B1 (pl) 2013-04-30
HK1085380A1 (en) 2006-08-25
NO20180874A1 (no) 2005-06-24
ES2645924T3 (es) 2017-12-11
CA2503871A1 (fr) 2004-05-13
EP1575612B1 (fr) 2007-01-24

Similar Documents

Publication Publication Date Title
MA27644A1 (fr) Sechage
Cláudio et al. Extraction of vanillin using ionic-liquid-based aqueous two-phase systems
WO2005105978A3 (fr) Methode de deshydratation
Vårdal et al. Parallel artificial liquid membrane extraction of new psychoactive substances in plasma and whole blood
BRPI0614156A2 (pt) veìculo de dispensação de droga, método para tratar uma formulação de isobutirato de acetato de sacarose, e, formulação de isobutirato de acetato de sacarose
WO2018207493A1 (fr) Procédé de production de tissu décellularisé, tissu décellularisé et appareil de production de tissu décellularisé
Ge et al. Ultra-hydrophobic ionic liquid 1-hexyl-3-methylimidazolium tris (pentafluoroethyl) trifluorophosphate supported hollow-fiber membrane liquid–liquid–liquid microextraction of chlorophenols
CN112218940A (zh) 组合物、细胞保存组合物、细胞培养组合物、细胞制剂、包含微小气泡的对象物的制造方法、细胞的保存方法、细胞的培养方法和细胞制剂的制造方法
Vorobei et al. Effect of solvent type and concentration on size and morphology of arbidol microparticles obtained by supercritical antisolvent precipitation
Rajput et al. Volumetric, ultrasonic and viscometric behavior of nucleosides (uridine and cytidine) in aqueous L-ascorbic acid solutions at different temperatures
Banipal et al. Influence of polyhydroxy compounds on the micellization behaviour of cetyltrimethylammonium bromide: Conductance and microcalorimetric investigations
Montalbán et al. Extraction of organic compounds involved in the kinetic resolution of rac-2-pentanol from n-hexane by imidazolium-based ionic liquids: Liquid-liquid equilibrium
US9028806B2 (en) Method for impregnation with supercritical CO2
Liger-Belair Modeling the losses of dissolved CO2 from laser-etched champagne glasses
Panisello et al. Polysulfone microcapsules with different wall morphology
JP6452552B2 (ja) Ｔｉｅ２活性化剤、血管の成熟化剤、血管の安定化剤、及びリンパ管の安定化剤、並びにＴｉｅ２活性化用経口組成物
Goswami et al. Estimation of the theoretical pore sizes of the porcine oral mucosa for permeation of hydrophilic permeants
KR102170146B1 (ko) Pca 공정을 이용한 배양액의 결정화 장치 및 방법
KR100522206B1 (ko) 초임계유체추출기술을 이용한 참기름의 추출방법
Wienen et al. Enzyme release into the interstitial space of the isolated rat heart induced by changes in contractile performance
Hassenklöver et al. Atomisation of solid suspensions with dissolved inert gases
Liu et al. Solubility of organic acids in ethyl acetate expanded with CO2
Bandral et al. Effect of semicarbazide hydrochloride on the physicochemical properties of L-leucine and glycylglycine at varied temperatures and compositions
JP2012213347A (ja) 細胞への薬物導入用組成物およびその方法
Gulaboski Solutions used in Medicine-Definitions, Properties, Applications